MediciNova (MNOV) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

MNOV · Stock Price

USD 1.43-0.13 (-8.33%)

Market Cap: $69.9M

Historical price data

Market Cap: $69.9MPipeline: 21 drugs (1 Phase 3)Founded: 2000HQ: La Jolla, United States

Sector Ranking#289 in Small Molecule Drugs #67 in Neuroscience & CNS

Overview

MediciNova employs a capital-efficient 'search and develop' model, building a pipeline through strategic in-licensing of clinical-stage compounds. Founded in 2000 with Japanese venture backing, it has achieved dual public listings on NASDAQ and the Osaka Exchange. The company's current strategic focus is on three core assets: MN-166 (ibudilast) for neurological disorders, MN-221 for acute asthma/COPD exacerbations, and MN-001 for fibrotic diseases, aiming to create value through clinical milestones and strategic partnerships.

NeurologyRespiratoryFibrotic Diseases

Technology Platform

A 'Search and Develop' (S&D) platform focused on the strategic identification, in-licensing, and clinical development of de-risked, small-molecule therapeutics, primarily sourced from Japanese pharmaceutical partners.

Pipeline

21

21 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
MN-166 + placebo	Amyotrophic Lateral Sclerosis	Phase 2/3
Ibudilast + Placebo oral capsule	Alcohol Use Disorder	Phase 2
MN-166 (50 mg) First + Placebo First	Opioid Abuse	Phase 2
MN-001 + Placebo	Idiopathic Pulmonary Fibrosis	Phase 2
Dose Group 1 + MN-221 placebo + Dose Group 2 + Dose Group 3	Asthma	Phase 2

Funding History

3

Total raised:$75M

PIPE$20MUndisclosedMay 15, 2020

PIPE$25MUndisclosedDec 15, 2015

IPO$30MUndisclosedFeb 3, 2006

Opportunities

Lead programs target large, high-need markets in neurology, respiratory, and NASH, where successful approval could drive significant value.

The capital-efficient 'search and develop' model allows for pipeline diversification with lower upfront R&D risk.

Dual U.S./Japan listings and strong Japanese partner networks provide unique financing and deal-making avenues.

Risk Factors

High risk of clinical failure in expensive late-stage trials for lead assets.

The pre-revenue, micro-cap status creates persistent financing risk and potential for severe shareholder dilution.

All target markets are intensely competitive, threatening commercial potential even with regulatory approval.

Competitive Landscape

MN-166 faces competition from approved and pipeline therapies in progressive MS and ALS. MN-221 must differentiate from generic standard-of-care in acute asthma/COPD. MN-001 enters the highly crowded NASH arena, requiring compelling efficacy data to stand out against numerous late-stage competitors. MediciNova's edge lies in its differentiated mechanisms and capital-efficient development approach.